

Golimumab Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.9 28.09.2024 26416-00027 Date of first issue: 29.10.2014

SECTION 1: IDENTIFICATION

Product name : Golimumab Formulation

Manufacturer or supplier's details

Company : MSD

Address : Building A - Level 1/26 Talavera Rd

Macquarie Park NSW, Australia 2113

Telephone : 1 800 033 461

Emergency telephone number : Poisons Information Centre: Phone 13 11 26

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification

Respiratory sensitisation : Category 1

GHS label elements

Hazard pictograms :

Signal word : Danger

Hazard statements : H334 May cause allergy or asthma symptoms or breathing

difficulties if inhaled.

Precautionary statements : Prevention:

P261 Avoid breathing mist or vapours. P284 Wear respiratory protection.

Response:

P304 + P340 IF INHALED: Remove person to fresh air and

keep comfortable for breathing.

P342 + P311 If experiencing respiratory symptoms: Call a

POISON CENTER/ doctor.

Disposal:

P501 Dispose of contents/ container to an approved waste



Golimumab Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.9 28.09.2024 26416-00027 Date of first issue: 29.10.2014

disposal plant.

Other hazards which do not result in classification

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)	
Golimumab	476181-74-5	>= 10 -< 30	

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

If not breathing, give artificial respiration. If breathing is difficult, give oxygen.

Get medical attention.

In case of skin contact : Wash with water and soap as a precaution.

Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur.

Rinse mouth thoroughly with water.

Most important symptoms

and effects, both acute and

delayed

May cause allergy or asthma symptoms or breathing difficul-

ties if inhaled.

Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reac-

tive airways dysfunction syndrome).

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire- : Exposure to combustion products may be a hazard to health.



Golimumab Formulation

SDS Number: Date of last issue: 06.04.2024 Version Revision Date: 3.9 28.09.2024 26416-00027 Date of first issue: 29.10.2014

fighting

Hazardous combustion prod: :

Carbon oxides Sulphur oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- :

tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation

Use only with adequate ventilation. Do not breathe mist or vapours. Advice on safe handling

Do not swallow.

Avoid contact with eyes.



Golimumab Formulation

SDS Number: Date of last issue: 06.04.2024 Version Revision Date: 3.9 28.09.2024 26416-00027 Date of first issue: 29.10.2014

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

Keep container tightly closed.

Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respira-

tory irritants or sensitisers.

Take care to prevent spills, waste and minimize release to the

environment.

If exposure to chemical is likely during typical use, provide eye Hygiene measures

flushing systems and safety showers close to the working

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

Conditions for safe storage Keep in properly labelled containers.

Keep tightly closed.

Store in accordance with the particular national regulations.

Do not store with the following product types: Materials to avoid

Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Golimumab	476181-74-5	TWA	70 μg/m3 (OEB 3)	Internal

Engineering measures Ensure adequate ventilation, especially in confined areas.

Minimize workplace exposure concentrations.

Personal protective equipment

Respiratory protection If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type Particulates type

Hand protection

Material Chemical-resistant gloves

Choose gloves to protect hands against chemicals depending Remarks

on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the

end of workday.



Golimumab Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.9 28.09.2024 26416-00027 Date of first issue: 29.10.2014

Eye protection : Wear the following personal protective equipment:

Safety glasses

Skin and body protection : Skin should be washed after contact.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Aqueous solution

Colour : opalescent

Odour : No data available

Odour Threshold : No data available

pH : 5.5

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Solubility(ies)

Water solubility : soluble

Partition coefficient: n-

octanol/water

: No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available



Golimumab Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.9 28.09.2024 26416-00027 Date of first issue: 29.10.2014

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reac- : Can react with strong oxidizing agents.

tions

Conditions to avoid : None known. Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.

products

SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation

Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:

Golimumab:

Exposure routes : Inhalation

Assessment : May cause sensitisation by inhalation.



Golimumab Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.9 28.09.2024 26416-00027 Date of first issue: 29.10.2014

Chronic toxicity

Germ cell mutagenicity

Not classified based on available information.

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Not classified based on available information.

Components:

Golimumab:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Mouse, male

Application Route: Intravenous injection

Fertility: NOAEL Parent: 40 mg/kg body weight

Test Type: Fertility/early embryonic development

Species: Mouse, female

Application Route: Intravenous injection

Fertility: NOAEL Parent: 40 mg/kg body weight

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Monkey

Teratogenicity: NOAEL: 100 mg/kg body weight

Embryo-foetal toxicity: NOAEL: 100 mg/kg body weight

Test Type: Development

Species: Monkey

Developmental Toxicity: NOAEL F1: 50 mg/kg body weight

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Intravenous injection
Teratogenicity: NOAEL: 40 mg/kg body weight

Embryo-foetal toxicity: NOAEL: 40 mg/kg body weight Result: negative, No effects on foetal development

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Golimumab:

Species : Monkey NOAEL : 50 mg/kg



Golimumab Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.9 28.09.2024 26416-00027 Date of first issue: 29.10.2014

Application Route : Intravenous Exposure time : 6 Months Number of exposures : Intermittent

Species : Monkey
NOAEL : 25 mg/kg
Application Route : Subcutaneous
Exposure time : 6 Months

Species : Mouse
NOAEL : 40 mg/kg
Application Route : Intravenous

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Golimumab:

Inhalation : Symptoms: mild infections, upper respiratory tract infection,

viral infections, bronchitis, sinusitis, fungal infections

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Golimumab:

Ecotoxicology Assessment

Acute aquatic toxicity : No data available

Chronic aquatic toxicity : No data available

Persistence and degradability

No data available

Bioaccumulative potential

No data available

Mobility in soil

No data available

Other adverse effects

No data available



Golimumab Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.9 28.09.2024 26416-00027 Date of first issue: 29.10.2014

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

Environmentally hazardous : no

IATA-DGR

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo : Not applicable

aircraft)

Packing instruction (passen: Not applicable

ger aircraft)

IMDG-Code

UN number Not applicable Proper shipping name Not applicable Not applicable Class Not applicable Subsidiary risk Packing group Not applicable Labels Not applicable **EmS Code** Not applicable Marine pollutant Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

ADG

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable



Golimumab Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.9 28.09.2024 26416-00027 Date of first issue: 29.10.2014

Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Hazchem Code : Not applicable

Special precautions for user

Not applicable

Standard) Instrument

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mix-

Therapeutic Goods (Poisons: No poison se

No poison schedule number allocated (Please use the original publication to check for specific uses, specific conditions or

threshold limits that might apply for this chemical)

Prohibition/Licensing Requirements : There is no applicable prohibition,

authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regula-

tions

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16: ANY OTHER RELEVANT INFORMATION

Further information

Revision Date : 28.09.2024

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD

compile the Safety Data eChem Portal search results and European Chemicals Agen-

Sheet cy, http://echa.europa.eu/

Date format : dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and



Golimumab Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.9 28.09.2024 26416-00027 Date of first issue: 29.10.2014

Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China: IMDG - International Maritime Dangerous Goods: IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN